Wall Street is getting déjà vu from the worst group chat notification of 2020. A hantavirus outbreak aboard a cruise ship is reviving the same market divide that once defined pandemic-era trading, sending biotech stocks soaring while cruise operators and travel names fall back into selloff mode.

Riding the outbreak wave: ModernaMRNA

has emerged as the trade’s clearest winner, with shares surging 20% over the past week. The rally accelerated after the company confirmed it has been conducting “early-stage and ongoing” hantavirus research with the US Army Medical Research Institute of Infectious Diseases and Korea University’s Vaccine Innovation Center. The update added to investor excitement, given that hantavirus still has no approved vaccine or targeted antiviral treatment. Analysts called the rally “sentiment-driven rather than fundamental,” noting the disease remains a structurally small market with low incidence rates.

• The rally also spread to other pharma names like Inovio PharmaceuticalsINO
  and NovavaxNVAX
  , despite neither company having an active commercial hantavirus product.
• Analysts remain skeptical, with Evercore ISI saying Moderna “tends to trade on outbreak headlines” and sees “no meaningful revenue opportunity” from the current scare.

Cruise Lines Sail Into Rough Waters Again

Travel investors remain highly sensitive to outbreak headlines. The situation escalated over the weekend as countries began evacuating and quarantining passengers from the MV Hondius aboard military and government aircraft, with some travelers testing positive after returning home. The selloff hit an industry already struggling with high fuel costs, slowing bookings, and debt accumulated during the pandemic.

• Norwegian Cruise LineNCLH
  , CarnivalCCL
  , and Royal CaribbeanRCL
  are down roughly 27%, 18%, and 6% year-to-date, reflecting growing pressure across the sector.
• Norwegian recently warned that “softer travel demand and geopolitical uncertainty are weighing on bookings” while unveiling additional cost-cutting measures to stabilize profits.

The fear trade comeback: The hantavirus outbreak involved the Andes strain, the only known variant capable of person-to-person transmission — though such spread remains rare. While WHO Director-General Tedros Adhanom Ghebreyesus insisted hantavirus is “not another COVID” and stressed the low public health risk, the market’s knee-jerk reaction suggests investors still carry deep pandemic-era anxieties. The fastest-moving contagion on Wall Street might still be fear itself.